Dr Nicola Cresti
| Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom | 2024 |
|
Dr Ruth Norris
Dr Rosie Dew
Professor Alastair Greystoke
Dr Nicola Cresti
Henry Cain
et al. | Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study | 2024 |
|
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
| Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0) | 2023 |
|
Dr Sam Orange
Dr Nicola Cresti
| Effect of exercise before and/or during taxane-containing chemotherapy treatment on chemotherapy-induced peripheral neuropathy symptoms in women with breast cancer: systematic review and meta-analysis | 2023 |
|
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al. | Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide | 2017 |
|
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al. | A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours | 2016 |
|
Dr Despoina Televantou
Dr Nicola Cresti
| Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study | 2016 |
|
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
et al. | Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance | 2016 |
|
Dr Nicola Cresti
Dr Linda Hogarth
| Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases. | 2015 |
|
